147 related articles for article (PubMed ID: 23863507)
1. Long-term survival and outcome of patients originally given Mycobacterium vaccae for metastatic malignant melanoma.
Cananzi FC; Mudan S; Dunne M; Belonwu N; Dalgleish AG
Hum Vaccin Immunother; 2013 Nov; 9(11):2427-33. PubMed ID: 23863507
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma.
O'Brien ME; Saini A; Smith IE; Webb A; Gregory K; Mendes R; Ryan C; Priest K; Bromelow KV; Palmer RD; Tuckwell N; Kennard DA; Souberbielle BE
Br J Cancer; 2000 Oct; 83(7):853-7. PubMed ID: 10970684
[TBL] [Abstract][Full Text] [Related]
3. Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes.
Maraveyas A; Baban B; Kennard D; Rook GA; Westby M; Grange JM; Lydyard P; Stanford JL; Jones M; Selby P; Dalgleish AG
Ann Oncol; 1999 Jul; 10(7):817-24. PubMed ID: 10470429
[TBL] [Abstract][Full Text] [Related]
4. Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with Stage IV melanoma.
Tagawa ST; Cheung E; Banta W; Gee C; Weber JS
Cancer; 2006 Mar; 106(6):1353-7. PubMed ID: 16475151
[TBL] [Abstract][Full Text] [Related]
5. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings.
Belli F; Testori A; Rivoltini L; Maio M; Andreola G; Sertoli MR; Gallino G; Piris A; Cattelan A; Lazzari I; Carrabba M; Scita G; Santantonio C; Pilla L; Tragni G; Lombardo C; Arienti F; Marchianò A; Queirolo P; Bertolini F; Cova A; Lamaj E; Ascani L; Camerini R; Corsi M; Cascinelli N; Lewis JJ; Srivastava P; Parmiani G
J Clin Oncol; 2002 Oct; 20(20):4169-80. PubMed ID: 12377960
[TBL] [Abstract][Full Text] [Related]
6. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine.
Bystryn JC; Zeleniuch-Jacquotte A; Oratz R; Shapiro RL; Harris MN; Roses DF
Clin Cancer Res; 2001 Jul; 7(7):1882-7. PubMed ID: 11448900
[TBL] [Abstract][Full Text] [Related]
7. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes.
Morton DL; Hsueh EC; Essner R; Foshag LJ; O'Day SJ; Bilchik A; Gupta RK; Hoon DS; Ravindranath M; Nizze JA; Gammon G; Wanek LA; Wang HJ; Elashoff RM
Ann Surg; 2002 Oct; 236(4):438-48; discussion 448-9. PubMed ID: 12368672
[TBL] [Abstract][Full Text] [Related]
8. Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.
BioDrugs; 2003; 17(1):69-72. PubMed ID: 12534322
[TBL] [Abstract][Full Text] [Related]
9. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines.
Smith FO; Downey SG; Klapper JA; Yang JC; Sherry RM; Royal RE; Kammula US; Hughes MS; Restifo NP; Levy CL; White DE; Steinberg SM; Rosenberg SA
Clin Cancer Res; 2008 Sep; 14(17):5610-8. PubMed ID: 18765555
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase II trial of SRL172 (Mycobacterium vaccae) +/- low-dose interleukin-2 in the treatment of metastatic malignant melanoma.
Nicholson S; Guile K; John J; Clarke IA; Diffley J; Donnellan P; Michael A; Szlosarek P; Dalgleish AG
Melanoma Res; 2003 Aug; 13(4):389-93. PubMed ID: 12883365
[TBL] [Abstract][Full Text] [Related]
11. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma.
Morton DL
Dev Biol (Basel); 2004; 116():209-17; discussion 229-36. PubMed ID: 15603194
[TBL] [Abstract][Full Text] [Related]
12. TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma.
Hsueh EC; Gupta RK; Qi K; Yee R; Leopoldo ZC; Morton DL
Cancer J Sci Am; 1997; 3(6):364-70. PubMed ID: 9403050
[TBL] [Abstract][Full Text] [Related]
13. Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine.
Takeuchi H; Morton DL; Elashoff D; Hoon DS
Int J Cancer; 2005 Dec; 117(6):1032-8. PubMed ID: 15986442
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report.
Dillman RO; Selvan SR; Schiltz PM; McClay EF; Barth NM; DePriest C; de Leon C; Mayorga C; Cornforth AN; Allen K
Cancer Biother Radiopharm; 2009 Jun; 24(3):311-9. PubMed ID: 19538053
[TBL] [Abstract][Full Text] [Related]
15. Effect of Mycobacterium vaccae on atopic dermatitis in children of different ages.
Arkwright PD; David TJ
Br J Dermatol; 2003 Nov; 149(5):1029-34. PubMed ID: 14632810
[TBL] [Abstract][Full Text] [Related]
16. Re-induction using whole cell melanoma vaccine genetically modified to melanoma stem cells-like beyond recurrence extends long term survival of high risk resected patients - updated results.
Mackiewicz J; Burzykowski T; Iżycki D; Mackiewicz A
J Immunother Cancer; 2018 Nov; 6(1):134. PubMed ID: 30486884
[TBL] [Abstract][Full Text] [Related]
17. A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire.
Batliwalla FM; Bateman BA; Serrano D; Murray D; Macphail S; Maino VC; Ansel JC; Gregersen PK; Armstrong CA
Mol Med; 1998 Dec; 4(12):783-94. PubMed ID: 9990864
[TBL] [Abstract][Full Text] [Related]
18. Effect of pre-immunization by killed Mycobacterium bovis and vaccae on immunoglobulin E response in ovalbumin-sensitized newborn mice.
Tükenmez F; Bahçeciler NN; Barlan IB; Başaran MM
Pediatr Allergy Immunol; 1999 May; 10(2):107-11. PubMed ID: 10478612
[TBL] [Abstract][Full Text] [Related]
19. Lack of elevation of serum S100B in patients with metastatic melanoma as a predictor of outcome after induction with an autologous vaccine of proliferating tumor cells and dendritic cells.
Schiltz PM; Dillman RO; Korse CM; Cubellis JM; Lee GJ; De Gast GC
Cancer Biother Radiopharm; 2008 Apr; 23(2):214-21. PubMed ID: 18454690
[TBL] [Abstract][Full Text] [Related]
20. The ability of heat-killed Mycobacterium vaccae to stimulate a cytotoxic T-cell response to an unrelated protein is associated with a 65 kilodalton heat-shock protein.
Skinner MA; Prestidge R; Yuan S; Strabala TJ; Tan PL
Immunology; 2001 Feb; 102(2):225-33. PubMed ID: 11260328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]